Revenue declined 10% in 2025, with Q4 hit by a major customer loss, but EBITDA margin improved to 21% due to cost controls. A one-time 116 MSEK impairment drove a large net loss, while cash flow turned positive in Q4. Focus shifts to core regulated markets and new leadership in 2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.